中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值在重症新型冠状病毒肺炎患者中的诊断价值——中国，2020年1月21日至2月10日，7例血浆吸附治疗病例
Diagnostic Value of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Patients with Severe COVID-19 - 7 PLADs, China, January 21-February 10, 2020.
作者信息
Ma Yan, Zhu Dongshan, Shi Nannan, Zhang Lei, Chen Guangkun, Ge Youwen, Zhang Zelei, Chen Renbo, Liu Sihong, Fan Yipin, Zhang Huamin, Wang Yanping
机构信息
Department of Infectious Disease Prevention, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
Department of Epidemiology, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, China.
出版信息
China CDC Wkly. 2022 Mar 11;4(10):195-198. doi: 10.46234/ccdcw2022.047.
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: Coronavirus disease 2019 (COVID-19) causes symptoms ranging from mild to severe. Indicators for identifying severe COVID-19 infection have not been well identified, especially for young patients.
WHAT IS ADDED BY THIS REPORT?: Both neutrophil-lymphocyte ratio (NLR) [area under curve (AUC): 0.80; the odds ratios (OR) and 95% confidence intervals (95% CI): 1.30 (1.13-1.50)] and platelet-lymphocyte ratio (PLR) [AUC: 0.87; OR (95% CI): 1.05 (1.01-1.09)] were determined to be indicators for recognition of patients with severe COVID-19 in young patients less than age 40.
WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: NLR and PLR are useful indicators for identifying patients with severe COVID-19, especially in young patients less than age 40.
关于该主题已了解的信息
2019年冠状病毒病（COVID-19）的症状从轻症到重症不等。识别重症COVID-19感染的指标尚未得到很好的确定，尤其是对于年轻患者。
本报告新增的内容
中性粒细胞与淋巴细胞比值（NLR）[曲线下面积（AUC）：0.80；比值比（OR）和95%置信区间（95%CI）：1.30（1.13 - 1.50）]和血小板与淋巴细胞比值（PLR）[AUC：0.87；OR（95%CI）：1.05（1.01 - 1.09）]被确定为40岁以下年轻患者中识别重症COVID-19患者的指标。
对公共卫生实践的意义
NLR和PLR是识别重症COVID-19患者的有用指标，尤其是在40岁以下的年轻患者中。
Zotero 插件